CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company developing its lead product candidate, Lasmiditan, for the acute treatment of migraine headaches, will relocate its corporate headquarters to the Cambridge, Massachusetts area. The Company is currently operating in Burlington while it searches for office space.
"We are very proud to have been a North Carolina-based company since our inception. However, given the expansion of our management team with Massachusetts-based executives, we feel it is the right time to relocate. Cambridge is the heart of the biotechnology industry and we are very excited to be a part of all the innovation and excitement that takes place here every day," said Thomas P. Mathers, CEO of CoLucid.
"We are thrilled to welcome CoLucid Pharmaceuticals to the Massachusetts life sciences community," said Robert K. Coughlin, President/CEO of MassBio, the Massachusetts life sciences trade association. "We know CoLucid will thrive in the ecosystem of innovation and collaboration here in the Commonwealth as they work to advance treatments for CNS disorders."